Statement from Arranta Bio on settlement of Thermo Fisher litigation
Arranta Bio, a Recipharm company and leading contract development and manufacturing organization (CDMO) supporting advanced therapy pioneers, has announced that it has doubled capacity at its Watertown, MA facility for process development services supporting RNA therapeutics. This major development comes less than a year after the acquisition of Arranta Bio by Recipharm, demonstrating Recipharm’s continued focus on the advanced therapeutics market. The expansion includes the fit out of approximately 2,000 ft2 of state-of-the-art laboratory space with flexible, modular small scale and pilot scale equipment to enable rapid development and scale up to GMP manufacturing.
Recipharm, a leading global contract development and manufacturing organisation (CDMO), today announces the closing of its acquisitions of advanced therapy CDMO Arranta Bio and virotherapy CDMO Vibalogics.
The CDMO has picked up Arranta Bio and Vibalogics in a two-pronged bid to beef up in biologics. Arranta specializes in microbiome therapeutic products and mRNA clinical production, while Vibalogics focuses on the production of oncolytic viruses, viral vaccines and gene therapies. The latter company also provides process and analytical development, manufacturing, testing and fill-finish services.
Arranta Bio, a contract development and manufacturing organization (CDMO) supporting advanced therapy pioneers, has completed the sale of its process development and GMP clinical manufacturing site in Gainesville, Florida, to Inceptor Bio and the transfer of client programs and key technical employees to Arranta’s Watertown, MA facility
Arranta Bio, a contract development and manufacturing organization (CDMO) supporting advanced therapy pioneers, unveiled plans to establish contract manufacturing capacity for messenger RNA (mRNA) vaccines. Arranta will offer the first end-to-end platform for full integration of cGMP manufacturing of critical raw materials, in-vitro transcription, mRNA purification, LNP formulation and sterile fill/finish all within its Watertown, MA facility. Arranta intends to support product innovators using an mRNA platform to develop vaccines, for example, vaccines targeting infectious diseases, as well as therapeutic vaccines, such as those targeting cancer.
Arranta Bio, a microbiome contract development and manufacturing organization (CDMO), has added a 130,000 square foot facility in Boxborough, MA, to complement its existing facilities in Watertown, MA and Gainesville, FL, bringing the total manufacturing capacity at Arranta to over 230,000 square feet. Arranta closed an oversubscribed Series B equity financing from its current investors to fund the expansion.